Oxybutynin chloride and Central nervous system lesion - a phase IV clinical study of FDA data

Summary:

Central nervous system lesion is reported as a side effect among people who take Oxybutynin chloride (oxybutynin chloride), especially for people who are female, 50-59 old, also take Ampyra, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Central nervous system lesion when taking Oxybutynin chloride. It is created by eHealthMe based on reports of 10,417 people who have side effects when taking Oxybutynin chloride from the FDA, and is updated regularly.

What is Oxybutynin chloride?

Oxybutynin chloride has active ingredients of oxybutynin chloride. It is often used in urge incontinence. eHealthMe is studying from 10,830 Oxybutynin chloride users. Check the latest studies of Oxybutynin chloride.

What is Central nervous system lesion?

Central nervous system lesion (an abnormality in tissue of brain or spinal cord) is found to be associated with 779 drugs and 824 conditions by eHealthMe. Check the latest studies of Central nervous system lesion.

On Jul, 26, 2026

10,417 people reported to have side effects when taking Oxybutynin chloride.
Among them, 38 people (0.36%) have Central nervous system lesion.

Could Oxybutynin chloride cause Central nervous system lesion?

Among these 38 people:

What is the gender of people who have Central nervous system lesion when taking Oxybutynin chloride? *

female: 76.32 %
male: 23.68 %

What is the age of people who have Central nervous system lesion when taking Oxybutynin chloride? *

What are other drugs people take besides Oxybutynin chloride? *

What are other side effects people have besides Central nervous system lesion? *

Constipation: 12 people, 31.58%
Nausea (feeling of having an urge to vomit): 10 people, 26.32%
Fall: 10 people, 26.32%
Abdominal Distension: 9 people, 23.68%
Flatulence (flatus expelled through the anus): 9 people, 23.68%
Weakness: 8 people, 21.05%
Indigestion: 7 people, 18.42%
Skin Blushing/flushing (a sudden reddening of the face, neck): 7 people, 18.42%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 6 people, 15.79%
Balance Disorder: 6 people, 15.79%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 29 people, 76.32%
Gait Disturbance: 7 people, 18.42%
Insomnia (sleeplessness): 4 people, 10.53%
Dysthymia (mild chronic depression): 3 people, 7.89%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 3 people, 7.89%
Pain: 2 people, 5.26%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 2 people, 5.26%
Stress And Anxiety: 1 person, 2.63%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 2.63%
Depression: 1 person, 2.63%

* Approximation only. Some reports may have incomplete information.

Do you take Oxybutynin chloride and have Central nervous system lesion?

- Check whether Central nervous system lesion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Oxybutynin chloride:

Oxybutynin chloride (10,830 reports)

Browse all side effects of Oxybutynin chloride:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Central nervous system lesion:

Central nervous system lesion (779 drugs)

Browse all the conditions that are associated with Central nervous system lesion:

Central nervous system lesion (824 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on oxybutynin chloride (the active ingredients of Oxybutynin chloride) and Oxybutynin chloride (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.